menu
    • menu
    [{"orgOrder":0,"company":"BMI Korea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"BMI2006","moa":"SNAP25","graph1":"Dermatology","graph2":"Phase III","graph3":"BMI Korea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BMI Korea \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BMI Korea \/ Undisclosed"},{"orgOrder":0,"company":"BMI Korea","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BMI2004","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"BMI Korea","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BMI Korea \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BMI Korea \/ Undisclosed"},{"orgOrder":0,"company":"BMI Korea","sponsor":"Brexogen","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"BxC-I17e","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I","graph3":"BMI Korea","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BMI Korea \/ BMI Korea","highestDevelopmentStatusID":"6","companyTruncated":"BMI Korea \/ BMI Korea"},{"orgOrder":0,"company":"BMI Korea","sponsor":"EYEGENE","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"BMI Korea","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"BMI Korea \/ BMI Korea","highestDevelopmentStatusID":"9","companyTruncated":"BMI Korea \/ BMI Korea"}]

    Find Clinical Drug Pipeline Developments & Deals by BMI Korea

    Menu

    BMI Korea

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BMI Korea

                            South Korea arrow
                            Neuroscience
                            Not Confirmed

                            BMI Korea

                            South Korea arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Recipient : EYEGENE

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years O...

                            Details : Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Meningococcal Infections.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            October 02, 2025

                            Lead Product(s) : Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Recipient : EYEGENE

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BMI Korea

                            South Korea arrow
                            Neuroscience
                            Not Confirmed

                            BMI Korea

                            South Korea arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BxC-I17e

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Recipient : Brexogen

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Brexogen, BMI Korea Form Exosome Therapy Tech Transfer Deal

                            Details : Under the icensing agreement, BMI Korea has secured the exclusive rights of BxC-I17e, an innovative exosome-based injectable therapeutics for the treatment of Atopic Dermatitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $2.3 million

                            February 19, 2025

                            Lead Product(s) : BxC-I17e

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Recipient : Brexogen

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BMI Korea

                            South Korea arrow
                            Neuroscience
                            Not Confirmed

                            BMI Korea

                            South Korea arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BMI2004

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Safety and Tolerability of a Single-dose Administration of BMI2004 Inj.

                            Details : BMI2004 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 28, 2023

                            Lead Product(s) : BMI2004

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BMI Korea

                            South Korea arrow
                            Neuroscience
                            Not Confirmed

                            BMI Korea

                            South Korea arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BMI2006

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treatment of Moderate to Severe Glabellar Lines (BMI2006)

                            Details : BMI2006 is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Glabellar Lines.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            September 08, 2022

                            Lead Product(s) : BMI2006

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth